natgillin/translations-raw huggingface dataset:
In a follow-up study conducted in 74 children, approximately 2.5 to 3 years after the booster dose, 85.3% of the children were still seroprotected against hepatitis B and at least 95.7% were seroprotected against the three poliovirus types and PRP.
V spremljevalni študiji pri 74 otrocih je bilo približno 2,5 do 3 leta po obnovitvenem odmerku 85,3 % otrok še vedno serološko zaščitenih proti hepatitisu B in vsaj 95,7 % serološko zaščitenih proti trem vrstam poliovirusa in PRP.
In a follow-up study where initially cleared patients with Imiquimod were followed for at least 14 months without any further AK-treatment, 40.5% of the patients showed sustained complete clearance of the whole treatment area (either full face or scalp) There are no data on long-term clearance beyond that.
V nadaljevalni študiji, v kateri so najmanj 14 mesecev opazovali bolnike, ki so se zdravili z imikvomod 3,75 % in pri katerih so lezije na začetku izginile, nato pa niso več prejemali kakršnega koli nadaljnjega zdravljenja AK, se je pri 40,5 % bolnikov pokazala trajna popolna odprava na celotnem zdravljenem področju (bodisi celotnem obrazu ali lasišču).
In a fourth study, the safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly vs 25 mg Enbrel administered twice weekly were evaluated in a double-blind, placebo- controlled study of 356 patients with active ankylosing spondylitis.
V četrti, dvojno slepi in s placebom nadzorovani študiji so pri 356 bolnikih z aktivnim ankilozirajočim spondilitisom vrednotili varnost in učinkovitost dajanja zdravila Enbrel v odmerku 50 mg enkrat na teden (dve 25 mg subkutani injekciji) v primerjavi z dajanjem zdravila Enbrel v odmerku 25 mg dvakrat na teden.
In a glass beaker of suitable size place the stated amount of water containing 0.05 % w/v sodium benzoate added as a preservative.
V stekleno čašo ustrezne velikosti dajte navedeno količino vode, ki vsebuje 0,05 % m/v natrijevega benzoata kot konzervans.
In a glass beaker of suitable size place the stated amount of water containing 0.05 % w/v sodium benzoate added as a preservative.
V temno obarvano stekleno čašo ustrezne velikosti dajte navedeno količino vode, ki vsebuje 0,05% m/v natrijevega benzoata dod anega kot konzervans.
In a group of 2,711 plaque psoriasis patients treated with Enbrel in double- blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin cancers were reported.
V skupini 2.711 bolnikov s psoriazo v plakih, zdravljenih z zdravilom Enbrel v dvojno slepih in odprtih študijah, ki so trajale do 2,5 leta, so poročali o 30 malignomih in 43 primerih nemelanomskega kožnega raka.
In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (oral aripiprazole 77 % and haloperidol 73 %).
V preskušanju, nadzorovanems haloperidolom, je bil delež odzivnih bolnikov, pri katerih se je odziv na zdravilo ohranil po 52 tednih, v obeh skupinah podoben (peroralni aripiprazol 77 % in haloperidol 73 %).
In a healthy subjects study, no significant change in nilotinib pharmacokinetics was observed when a single 400 mg dose of Tasigna was administered 10 hours after and 2 hours before famotidine.
V študiji z zdravimi preiskovanci niso opažali pomembnih sprememb farmakokinetike nilotiniba, če so preiskovancem odmerili posamezen odmerek 400 mg zdravila Tasigna 10 ur po odmerjanju famotidina oziroma 2 uri pred njim.
In a healthy volunteer drug interaction study of delamanid 100 mg twice daily and lopinavir/ritonavir 400/100 mg twice daily for 14 days, the exposure of the delamanid metabolite DM-6705 was 30% increased.
V študiji medsebojnega delovanja pri zdravih prostovoljcih, ki so 14 dni prejemali 100 mg delamanida dvakrat na dan in lopinavir/ritonavir 400/100 mg dvakrat na dan je bila izpostavljenost presnovka delamanida DM-6705 povečana za 30
In a interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC (+57%) of S-warfarin.
V raziskavi interakcij so pri jemanju enkratnega odmerka varfarina ugotovili pomembno povečanje povprečne AUC S-varfarina (+ 57 %).
In a interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC (+57%) of S-warfarin.
V raziskavi interakcij so pri jemanju enkratnega odmerka varfarina ugotovili pomembno povečanje povprečne AUC S-varfarina (+57 %).
In a juvenile rat toxicity study, where rats were treated from Day 4 post partum up to adulthood, decreased absolute weights of testes and epididymides, and reduced number of sperm in epididymides were observed after weaning.
V študiji toksičnosti pri podganjih mladičih, kjer so podgane tretirali od 4. dne po skotitvi do odraslosti, so po ukinitvi dajanja opazili zmanjšano obsolutno maso testisov in obmodkov ter zmanjšano število spermijev v obmodkih.
In a juvenile toxicity study in dogs treated from post natal day 14 to day 42, a decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and oedema of vaginal tissues were seen in females from 4 mg/kg/day.
V študiji toksičnosti pri mladih psih, ki so od 14. do 42. dne postnatalno dobivali aprepitant, so pri samcih opažali manjšo maso testisov in manjšo velikost Leydigovih celic pri odmerku mg/kg/dan, pri samicah pa večjo maso maternice, hipertrofijo maternice in materničnega vratu ter edem nožničnih tkiv pri odmerkih od 4 mg/kg/dan.
In a juvenile toxicity study in rats treated from post natal day 10 to day 63 aprepitant led to an earlier vaginal opening in females from 250 mg/kg b.i.d. and to a delayed preputial separation in males, from 10 mg/kg b.i.d.
V študiji toksičnosti pri mladih podganah, ki so od 10. do 63. dne po skotitvi dobivale aprepitant, je ta pri samicah povzročil zgodnejše odprtje nožnice pri odmerkih od 250 mg/kg dvakrat na dan in pri samcih zapoznelo ločitev prepucija pri odmerkih od 10 mg/kg dvakrat na dan.
In a juvenile toxicity study in which sexually immature rats were treated daily with 3 mg/kg for 7 weeks, atrophy of testes and epididymides were observed.
V študiji toksičnosti za razvoj mladičev, v kateri so spolno nezrele podgane zdravili s 3 mg/kg na dan 7 tednov, so opazili atrofijo testisa in epididimisa.
In a laboratory study, the development of papillomas was noted in a number of dogs.
Pri številnih prih, ki so prejeli zdravljenje v priporočenem odmerku, so v laboratorijski študiji opazili razvoj papilomov.
In a laboratory study, the development of papillomas was noted in a number of dogs.
Pri številnih psih, ki so prejeli zdravljenje v priporočenem odmerku, so v laboratorijski študiji opazili razvoj papilomov.
In a laboratory study, the use of an acepromazine/oxymorphone/thiopental/sevoflurane anaesthetic regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs anaesthetised with sevoflurane alone.
V laboratorijski raziskavi je uporaba anestezijske sheme z acepromazinom/oksimorfonom/ tiopentalom/sevofluranom povzročila podaljšano prebujanje pri vseh psih, ki so dobili ta zdravila, v primerjavi s psi, ki so jih anestezirali samo s sevofluranom.
In a lactation study in rats, there was minimal excretion of Rienso or Rienso-derived radioactivity into milk following single IV administration of approximately 100 mg Fe/kg (HED of 16.1 mg Fe/kg, approximately 2 times the recommended 510 mg human dose on a mg/m2 basis) of either the unlabelled, 59Fe or 14C-labelled product to lactating rats 10-11 days post-parturition, which peaked at 8 to 24 hours post-administration.
V študiji laktacije pri podganah je bilo zaznano minimalno izločanje zdravila Rienso ali radioaktivnosti iz zdravila Rienso v mleko po enem i.v. odmerku v višini približno 100 mg Fe/kg (kar ustreza odmerku 16,1 mg Fe/kg pri človeku, kar je približno 2-kratni priporočeni odmerek 510 mg pri človeku na osnovi mg/m2), neoznačenega ali s 59Fe ali 14C označenega zdravila, ki so ga dali podganam v obdobju laktacije 10–11 dni po kotitvi, z najvišjo vrednostjo 8 do 24 ur po dajanju.
In a large clinical trial in 7,736 patients, osteonecrosis of the jaw has been reported in one patient treated with zoledronic acid and one patient treated with placebo.
V obsežnem kliničnem preskušanju s 7.736 bolniki so o osteonekrozi čeljusti poročali pri enem bolniku, ki je prejemal zoledronsko kislino, in pri enem bolniku, ki je prejemal placebo.
In a large multicentre clinical trial, 20479 patients with acute STEMI who could be treated with fibrinolytic therapy were randomised to a group receiving 30 mg enoxaparin in a single intravenous bolus injection and, in addition, immediately after intravenous injection, subcutaneously 1 mg/kg bw, followed by 1 mg/kg bw subcutaneously every 12 hours; or to a group receiving intravenous heparin at a dose adjusted to the individual APTT for 48 hours.
V velikem multicentričnem kliničnem preskušanju so 20.479 bolnikov z akutnim STEMI, primernih za fibrinolitično terapijo, randomizirali bodisi v skupino, v kateri so prejemali enoksaparin v enkratni 30-mg intravenski bolusni injekciji in takoj po tem 1 mg/kg TM subkutano, čemur je sledilo injiciranje 1,0 mg/kg TM subkutano na 12 ur, bodisi v skupino, v kateri so 48 ur prejemali heparin intravensko v odmerku, prilagojenem glede aPTČ posameznika.
In a large multicentre clinical trial, 20479 patients with acute STEMI who could be treated with fibrinolytic therapy were randomised to a group receiving 30 mg enoxaparin in a single intravenous bolus injection and, in addition, immediately after intravenous injection, subcutaneously 1 mg/kg bw, followed by 1 mg/kg bw subcutaneously every 12 hours; or to a group receiving intravenous heparin at a dose adjusted to the individual APTT for 48 hours.
V velikem multicentričnem kliničnem preskušanju so 20.479 bolnikov z akutnim STEMI, primernih za fibrinolitično terapijo, randomizirali v skupino, v kateri so prejemali enoksaparin v enkratni 30-mg intravenski bolusni injekciji in takoj po tem 1 mg/kg TM subkutano, čemur je sledilo subkutano injiciranje 1,0 mg/kg TM na 12 ur, ali v skupino, v kateri so 48 ur intravensko prejemali heparin v odmerku, prilagojenem na aPTČ posameznika.
In a large outcome study (MERLIN-TIMI 36) in 6,560 patients with UA/NSTEMI ACS, there was no difference between Ranexa and placebo in the risk of all-cause mortality (relative risk ranolazine:placebo 0.99), sudden cardiac death (relative risk ranolazine:placebo 0.87), or the frequency of symptomatic documented arrhythmias (3.0% versus 3.1%).
V veliki študiji izida (MERLIN-TIMI 36), v kateri je sodelovalo 6560 bolnikov z akutnim koronarnim sindromom z nestabilno angino/infarktom miokarda brez povečanja intervala ST (unstable angina/non- ST-elevation myocardial infarction acute coronary syndrome- UA/NSTEMI ACS), med zdravilom Ranexa in placebom ni bilo razlike pri tveganju za umrljivost zaradi vseh vzrokov (relativno tveganje ranolazin : placebo 0,99), nenadno srčno smrt (relativno tveganje ranolazin : placebo 0,87) ali pogostnost dokumentiranih simptomatskih aritmij (3,0 % v primerjavi 3,1 %).
In a large outcome study (MERLIN-TIMI 36) in 6,560 patients with UA/NSTEMI ACS, there was no difference in the risk of all-cause mortality (relative risk ranolazine:placebo 0.99), sudden cardiac death (relative risk ranolazine:placebo 0.87), or the frequency of symptomatic documented arrhythmias (3.0% versus 3.1%) between Ranexa and placebo when added to standard medical therapy (including beta-blockers, calcium channel blockers, nitrates, anti-platelet agents, lipid-lowering medicinal products, and ACE inhibitors).
V veliki študiji izida (MERLIN-TIMI 36) pri 6560 bolnikih z UA/NSTEMI AKS ni bilo razlike pri tveganju za umrljivost zaradi vseh vzrokov (razmerje relativnega tveganja med ranolazinom in placebom 0,99), nenadni srčni smrti (razmerje relativnega tveganja med ranolazinom in placebom 0,87) ali pogostnosti simptomatičnih dokumentiranih aritmij (3,0 % v primerjavi s 3,1 %) med zdravilom Ranexa in placebom, kadar so ga dodali standardnemu zdravljenju (vključno z beta- blokatorji, zaviralci kalcijevih kanalčkov, nitrati, protitrombocitnimi zdravili, zdravili za zmanjšanje koncentracije lipidov in zaviralci ACE).
In a large phase III clinical study, antibodies to parathyroid hormone were detected in 3% of women receiving Preotact compared to 0.2% of women receiving placebo.
V veliki klinični študiji faze III so zaznali protitelesa proti obščitničnemu hormonu pri 3% žensk, ki so prejemale zdravilo Preotact, in pri 0,2% žensk, ki so prejemale placebo.
In a large study, 1,071 patients were enrolled after treatment in a prior non-pegylated interferon alfa- 2b or non-pegylated interferon alfa-2b/ribavirin study to evaluate the durability of sustained virologic response and assess the impact of continued viral negativity on clinical outcomes.
V veliko študijo so vključili skupaj 1.071 bolnikov, ki so bili predhodno vključeni v študijo z nepegiliranim interferonom alfa-2b ali z nepegiliranim interferonom alfa-2b in ribavirinom, da bi ovrednotili trajanje trajnega virološkega odziva in ocenili vpliv nadaljnjih negativnih izvidov določanja virusa na klinične izide.
In a large-scale phase III, randomized, double-blind clinical trial (Clinical Otitis Media and Pneumonia Study - COMPAS) conducted in Argentina, Panama and Colombia, healthy infants aged 6 to 16 weeks received either Synflorix or hepatitis B control vaccine at 2, 4 and 6 months of age followed respectively by either Synflorix or hepatitis A control vaccine at 15 to 18 months of age.
V velikem randomiziranem, dvojno slepem kliničnem preskušanju III. faze (Clinical Otitis Media and Pneumonia Study - COMPAS), ki je potekalo v Argentini, Panami in Kolumbiji, so zdravi dojenčki, stari od 6 do 16 tednov, pri 2, 4 in 6 mesecih starosti prejeli ali cepivo Synflorix ali kontrolno cepivo proti hepatitisu B, nato pa pri 15 do 18 mesecih starosti bodisi cepivo Synflorix bodisi kontrolno cepivo proti hepatitisu A.
In a large-scale phase III/IV, double-blind, cluster-randomized, controlled, clinical trial in Finland (FinIP), children were randomised into 4 groups according to the two infant vaccination schedules [2- dose (3, 5 months of age) or 3-dose (3, 4, 5 months of age) primary schedule followed by a booster dose as of 11 months of age] to receive either Synflorix (2/3rd of clusters) or hepatitis vaccines as control (1/3rd of clusters).
V obsežnem, dvojno slepem, klastersko randomiziranem, kontroliranem kliničnem preskušanju III./IV. faze na Finskem (FinIP), so otroke randomizirali v 4 skupine glede na dve shemi cepljenja [shema primarnega cepljenja z 2 odmerkoma (3. in 5. mesec starosti) ali s 3 odmerki (3., 4. in 5. mesec starosti) in nato obnovitveni odmerek od 11. meseca starosti]; preiskovanci so dobili ali cepivo Synflorix (2/3 klastrov) ali cepivo proti hepatitisu kot kontrolno cepivo (1/3 klastrov).
In a limited number of RA patients treated with subcutaneous golimumab over a 6-month period, concomitant use of MTX reduced the apparent clearance of golimumab by approximately 36%.
Pri omejenem številu bolnikov z revmatoidnim artritisom, ki so bili zdravljeni z golimumabom subkutano več kot 6 mesecev, je sočasna uporaba metotreksata zmanjšala navidezni očistek golimumaba za približno 36 %.
In a long term study, the dogs treated with PRILACTONE also showed less deterioration of their heart disease compared to the dogs which were treated only with ‘standard therapy’.
Pri dolgotrajni študiji se je prav tako manj poslabšalo stanje bolezni srca pri psih, ki so jih zdravili z zdravilom PRILACTONE, kot pri psih, ki so jih zdravili le s „standardnim zdravljenjem“.
In a long-term double-blind study in patients with PAH, hypotension was reported for 7.0% and 4.4% of patients on macitentan 10 mg and placebo, respectively.
V dolgoročni, dvojno slepi študiji pri bolnikih s PAH so o hipotenziji poročali pri 7,0 % bolnikih, ki so prejemali macitentan 10 mg, in pri 4,4 % bolnikih, ki so prejemali placebo.
In a long-term double-blind study in patients with PAH, the incidence of oedema AEs in the macitentan 10 mg and placebo treatment groups was 21.9% and 20.5%, respectively.
V dolgoročni, dvojno slepi študiji z bolniki s PAH je bila incidenca neželenega učinka edema 21,9 % v skupini, ki je prejemala macitentan 10 mg, in 20,5 % v skupini, ki je prejemala placebo.
In a long-term follow-up study of patients who had previously seroconverted and discontinued lamivudine, late virological relapse occurred in 39 % of the subjects.
V študiji dolgotrajnega spremljanja bolnikov, ki so se po serokonverziji prenehali zdraviti z lamivudinom, je pri 39 % oseb nastopil pozni virusni relaps.
In a long-term follow-up study of patients who had previously seroconverted and discontinued lamivudine, late virological relapse occurred in 39 % of the subjects.
V študiji dolgotrajnega spremljanja bolnikov, ki so se po serokonverziji prenehali zdraviti z lamivudinom, je pri 39 % oseb prišlo do poznega relapsa.
In a long-term follow-up study of patients who had previously seroconverted and discontinued lamivudine, late virological relapse occurred in 39 % of the subjects.
V študiji dolgotrajnega spremljanja bolnikov, ki so se po serokonverziji prenehali zdraviti z lamivudinom, je pri 39 % oseb prišlo do poznega virusnega relapsa.
In a long-term psoriasis study in which patients received 50 mg twice weekly for 96 weeks, the incidence of antibodies observed at each assessment point was up to approximately 9%.
V dolgoročni študiji psoriaze, v kateri so bolniki dobivali po 50 mg etanercepta dvakrat na teden 96 tednov, je bila incidenca protiteles, ki so jih našli pri posameznem periodičnem določanju, do približno 9 %.
In a long-term safety study (Kodiac 8), the frequency of AE reports of back pain was 8.9% for naloxegol 25 mg versus 8.8% for usual care.
V dolgoročni študiji varnosti (Kodiac 8) je bila pogostnost neželenega učinka »bolečine v hrbtu« v skupini s 25 mg naloksegola 8,9 % in v skupini z običajno oskrbo 8,8 %.
In a main study involving 1,072 patients with metastatic colorectal cancer which worsened despite treatment with bevacizumab, oxaliplatin and a fluoropyrimidine, those treated with Cyramza and FOLFIRI lived longer on average than patients treated with FOLFIRI and placebo: 13.3 months versus
V eni glavni študiji, v katero je bilo vključenih 1 072 bolnikov z metastatskim kolorektalnim rakom, pri katerih se je bolezen poslabšala kljub zdravljenju z bevacizumabom, oksaliplatinom ali fluoropirimidinom, so bolniki, zdravljeni z zdravilom Cyramza in kemoterapijo FOLFIRI, v povprečju živeli dlje kot bolniki, ki so prejemali kemoterapijo FOLFIRI in placebo: 13,3 meseca v primerjavi z 11,7 meseca.
In a main study involving 1,253 patients with advanced or metastatic non-small cell lung cancer which worsened despite treatment with medicines containing platinum, those treated with Cyramza and docetaxel lived longer on average than patients treated with docetaxel and placebo: 10.5 months versus 9.1 months respectively.
V eni glavni študiji, v katero je bilo vključenih 1 253 bolnikov z napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih se je bolezen poslabšala kljub zdravljenju z zdravili, ki vsebujejo platino, so bolniki, ki so prejemali zdravilo Cyramza in docetaksel, v poprečju živeli dlje kot bolniki, ki so prejemali docetaksel in placebo: 10,5 meseca v primerjavi z 9,1 meseca.
In a main study involving 742 patients, Opsumit has been shown to reduce the risk of PAH-related illness, particularly the worsening of PAH symptoms.
V glavni študiji, v katero so vključili 742 bolnikov, so pokazali, da zdravilo Opsumit zmanjša tveganje za bolezni, povezane s PAH, še posebno za poslabšanje simptomov PAH.
In a main study involving 760 patients with metastatic colorectal cancer which had progressed after standard therapy, Stivarga was compared with placebo (a dummy treatment) and the main measure of effectiveness was overall survival (the length of time that patients lived).
V glavni študiji, v katero je bilo vključenih 760 bolnikov z metastatskim kolorektalnim rakom, ki je napredoval po standardnem zdravljenju, so zdravilo Stivarga primerjali s placebom (zdravilom brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bilo celokupno preživetje (kako dolgo so bolniki živeli).
In a main study of 220 patients with previously treated CLL, Zydelig was shown to be more effective at treating the cancer than placebo (a dummy treatment) when both were given in combination with rituximab: 75% of patients taking Zydelig had an improvement in their disease compared with 15% of patients taking placebo.
V glavni študiji, v katero je bilo vključenih 220 bolnikov s predhodno zdravljeno kronično limfocitno levkemijo, se je zdravilo Zydelig izkazalo za učinkovitejše pri zdravljenju raka od placeba (zdravilo brez zdravilne učinkovine), pri čemer so bolniki oba prejemali v kombinaciji z rituksimabom: pri 75 % bolnikov, ki so prejemali zdravilo Zydelig, se je bolezen izboljšala v primerjavi s 15 % bolnikov, ki so prejemali placebo.
In a margin of safety study, the veterinary medicinal product was administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum exposure dose of 4 mg/kg at 28 day intervals for 10 doses.
V mejni varnostni študiji so zdravilo dajali peroralno 8 tednov starim psičkom pasme Beagle, v odmerkih, ki so bili 0, 1, 3 in 5 - krat večji od največjega priporočenega odmerka, (4 mg/kg telesne teže), po 10 odmerkov v 28 dnevnih presledkih.
In a mass balance study using 600 mg 14C-saquinavir (n = 8), 88 % and 1 % of the orally administered radioactivity, was recovered in faeces and urine, respectively, within 4 days of dosing.
V študiji masnega ravnovesja z uporabo 600 mg 14C-sakvinavirja (n = 8) so zaznali 88 % oziroma 1 % peroralno danega radioaktivno označenega v blatu oziroma urinu v 4 dneh po odmerjanju.
In a mass balance/excretion study in eight healthy male volunteers dosed to steady state with nevirapine 200 mg given twice daily followed by a single 50 mg dose of 14C-nevirapine, approximately 91.4 
V raziskavi o masni bilanci in izločanju pri osmih zdravih prostovoljcih, ki so do stanja dinamičnega ravnovesja prejemali odmerke nevirapina po 200 mg 2-krat na dan, nato enkratni odmerek po 50 mg
In a meta-analysis of 17 controlled clinical trials, elderly patients with dementia treated with other atypical antipsychotics, including risperidone, aripiprazole, olanzapine, and quetiapine had an increased risk of mortality compared to placebo.
V metaanalizi 17 nadzorovanih kliničnih preskušanj so pri starejših bolnikih z demenco, zdravljenih z drugimi atipičnimi antipsihotiki, vključno z risperidonom, aripiprazolom, olanzapinom in kvetiapinom, ugotovili zvečano tveganje za smrt v primerjavi s placebom.
In a meta-analysis of phase II and III studies, a total of 51 patients (dulaglutide: 26 [N = 3,885]; all comparators: 25 [N = 2,125]) experienced at least one cardiovascular (CV) event (death due to CV causes, nonfatal MI, nonfatal stroke, or hospitalisation for unstable angina).
V metaanalizi študij 2. in 3. faze je skupno 51 bolnikov (dulaglutid: 26 [N = 3885]; vsa primerjalna zdravila: 25 [N = 2125]) doživelo vsaj en kardiovaskularni (KV) dogodek (smrt zaradi KV-vzrokov, miokardni infarkt brez smrtnega izida, srčna kap brez smrtnega izida ali hospitalizacija zaradi nestabilne angine).
In a meta-analysis of six clinical trials, TAMs were not selected by regimens containing abacavir without zidovudine (0/127), but were selected by regimens containing abacavir and the thymidine analogue zidovudine (22/86, 26 %).
V metaanalizi šestih kliničnih preskušanj pri režimu, ki je vseboval abakavir brez zidovudina (0/127), selekcije mutacij timidinskih analogov niso ugotovili, ugotovili pa so jo pri režimih, ki so vsebovali abakavir in timidinski analog zidovudin (22/86, 26 %).